View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Yun Zhong
  • Yun Zhong

KOL Call Takeaways: WVE-006 Had A Good Start In AATD

Measuring Actual Outcomes Would be More Important. The level of protection required by each patient could be different. For some patients (e.g., those with more inflammation), a higher level (i.e., higher dose of augmentation therapy) could be required. Therefore, according to Dr. Hogarth, instead

David Nierengarten ... (+4)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
  • Yun Zhong

KOL Call Today @ 1PM ET: Just Breathe: Genetic Medicines in AATD

Dr. Hogarth completed his residency in internal medicine (1998-2001) and his fellowship in pulmonary and critical care medicine (2001-2004) before joining the University of Chicago faculty as an Assistant Professor of Medicine (2004-2014). He was later promoted to Associate Professor of Medicine (2

David Nierengarten ... (+4)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
  • Yun Zhong

KOL Call On Wednesday: Just Breathe: Genetic Medicines in AATD

Dr. Hogarth completed his residency in internal medicine (1998-2001) and his fellowship in pulmonary and critical care medicine (2001-2004) before joining the University of Chicago faculty as an Assistant Professor of Medicine (2004-2014). He was later promoted to Associate Professor of Medicine (2

David Nierengarten ... (+4)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
  • Yun Zhong
David Nierengarten ... (+4)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
  • Yun Zhong
 PRESS RELEASE

Wave Life Sciences Announces Virtual Research Day on October 29th and ...

Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that it will host a virtual Research Day on Wednesday, October 29, 2025 at 10:00 a.m. ET. In addition, members of Wave’s management team are scheduled to participate in several upcoming investor conferences. Details are as follows: Bernstein 2...

 PRESS RELEASE

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion...

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT)  First-ever demonstration of therapeutically restored physiological serum AAT production in a Pi*ZZ individual during a non-drug related acute phase response (20.6 µM total AAT, 10.3 µM M-AAT) Single dose of 400 mg achieved 12.8 µM total AAT and 5.3 µM M-AAT; ongoing 400 mg m...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan

Wave Life Sciences Ltd: 2 directors

Two Directors at Wave Life Sciences Ltd sold/sold after exercising options 227,351 shares at between 10.000USD and 10.098USD. The significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Speculative Areas Still Leading; Staying Bullish We have discussed since late-July how the S&P 500 (SPX) had not closed below its 20-day MA for three months, but that even when it does, "all we would expect to happen is for a new, less-steep uptrend to form." That is precisely what has happened after the SPX finally lost its 20-day MA (for one whole day) on 8/1/25, only to get back to all-time highs last week. Therefore, we remain near-term bullish since our 4/22/25 Compass, and our intermediat...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch